Effects of Testosterone and Gonadotropin Therapy in Men with Hypogonadotropic Hypogonadism

This Article

Citations


Article Information:


Group: 2009
Subgroup: Volume 7, Issue 4, Autumn
Date: December 2009
Type: Original Article
Start Page: 242
End Page: 247

Authors:

  • H Farshchi
  • Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran
  • A Shahnazi
  • Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran
  • F Azizi
  • Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran

      Correspondence:

      Affiliation: Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences
      City, Province: Tehran,
      Country: I.R. Iran
      Tel:
      Fax:
      E-mail: azizi@endocrine.ac.ir

Abstract:


Limited data is available on the treatment of male infertility in patients with hypogonadotropic hypogonadism (HH). The aim of this study was to evaluate the impact of therapy with testosterone and gonadotropins on the development of sexual characteristics and fertility in men with HH. Materials & Methods: In this study, conducted between 1992 and 2009, 102 male patients with HH were investigated. Patients who did not have secondary sexual characteristics were treated by testosterone until normalization of public hair and full appearance of sexual characteristics and 41 patients, who wanted fertility received treatment with human chronic gonadotropin (hCG), followed by human menopausal gonadotropin (hMG). Testicular volume, sperm production and fertility were assessed, before and after treatment. Results: Mean age at presentation was 22.7±6.3 years. Means for pubic hair and genital stages were 1.8±0.9 and 2.0±1.3, respectively. Testicular volume was 3.4±1.9 mL and 96% had azospermia. Levels of serum testosterone of 40±60 ng/dL, LH 0.5±1.0 IU/l and FSH 1.0±1.2 IU/l, were all in prepubertal ranges. Treatment with hMG/hCG in 32 men who completed >1 year of therapy, resulted in 24 conceptions (75%), 5 abortions and 19 pregnancies, with 18 singletons and one twin. Conclusion: Since treatment with gonadotropins resulted in conception in 75% and live births in 59% of the cases, it seems that in male patients with hypogonadotropic hypogonadism, this regimen is the treatment of choice.

Keywords: Hypogonadotropic hypogonadism; Testosterone; Gonadotropins

Manuscript Body:


Introduction
Infertility is an important issue for couples and male infertility disorders play a major role in pproximately 50% of the cases. In the vast majority, male infertility istreatable and medical therapies are used as an initial strategy to improve sperm production or as a preliminary therapy to boost production transiently in anticipation of a surgical sperm retrieval attempt.1-3 Male hypogonadotropic hypogonadism (HH), characterized by the absence of endogenous gonadotropin secretion, may be caused by pituitary tumors, isolated gonadotropin deficiency, panhypopituitarism,or pituitary trauma. Routine evaluation of patients includes a pituitary MRI to rule out a pituitary tumor. In addition, hyperprolactinemia should be ruled out and treated before the initiation of gonadotropin replacement therapy.2-4 In males, HH testosterone therapy is sufficient for maturation and maintenance of secondary sex characteristics. However, for stimulation of spermatogenesis administration of gonadotropins is necessary5. Currently available gonadotropin preparations include human chorionic gonadotropin (hCG), human menoppusal gonadotropin (hMG), urinary FSH, highly purified urinary FSH, and human recombinant FSH.6 If pulsatile gonadotrotpin-releasing hormone (GnRH) is not indicated or desired, hCG is used as the source of luteinizing hormone (LH) activity to stimulate testosterone sectetion by Leydig cells, whereas hMG is used as the source of follicle stimulating hormone (FSH)1. More recently, recombinant gonadotropins have also been used clinically.5-9 Hypogonadotropic hypogonadism is a rare cause of male infertility and there is limited data on its management, even in specialized centers. Here we aimed at investigating the effects of treatment of HH in a relativelylarge sample of Tehranian men with HH.

Materials and Methods
Patients
Between1992 and 2009, 102 male patients were diagnosed with HH based on their medical history, physical examinations, spermexamination and low serum concentrations of FSH,LH and total testosterone. Gonadotropin deficiency in 71 was a result of idiopathic HH and Kallmann syndrome, whereas in 31, the cause was pituitary insufficiency. Pituitary imaging by magnetic resonance imaging did not show any evidence of secondary HH. Patients who did not have secondary sexual characteristics(n=75)were treated with testosterone enanthate 250 mg by monthlyintramuscular injections until normalization of pubic and facial hair and development of the sexual male pattern; the others had been on testosterone therapy since 1 to 13 years, prior to visit and treatment was continued until they decided to have children. For induction of spermatogenesis we used hCG 1500 IU 3 times per week and added hMG treatment 75 IU subcutaneously, three times weekly, until successful induction of spermatogenesis and attainment of conception.

Follow up
The clinical and laboratory data including pubic hair stage, genital stage, testicular volume, sexual function and sperm production (sperm counts, sperm motility) were determined once for 102 controls and 102 patients, before and after hCG/hMG treatment. Testicular volume was measured with an ellipsoid orchidometer (Prader orchidometer, ASSI, NY) at baseline and after treatment. Serum testosterone was determined using radioimmunoassay and serum LH and FSH were analyzed by immunogluorometric assays (Delfia, Wallace, Freiburg, Germany). The inter-assay and intricacy variance of all assays did not exceed 7.0%. Characteristics of sperm were analyzed according to WHO guidelines1. Data were compared to those obtained from 102 age-matched normal men. Unpaired t test was used for comparison between the two groups, with paired t test being used to compare means before and after treatment.

Results
Baseline clinical and biochemical findings
The mean age of patients was 22.7±6.3y (range 15-39 y). Clinical characteristics of the entire study population are summarized in Table 1. Twenty-seven patients had been having testosterone or HCG treatment for some periods before presentation; however, all medications had been discontinued at least 3 months before evaluation three (72%) patients were followed for at least 2 years, following initiation of testosterone treatment. All developed secondary sexual characteristics, including increase in pubic hair, muscle development and strength, erection and ejaculation.The growth of facial hair was normalized only in 89%, who continued treatment for at least 4 years, while 11% had only partial growth of facial hair, despite long term hormone therapy.

Table1. Baseline clinical and biochemical characteristics of the 102 patients with hypogonadotropic hypogonadism at presentation and 102 normal controls

Variable Patients
(n=102)
Controls
(n=102)
Age (yr) 22.7±6.3 23.1±7.0
Pubic hair stage 1.8±0.9 4.8±0.8*
Genital stage 2.0±1.3 4.9±0.7*
Testicular volume
(mL)
3.4±1.9 14.5±7.7*
Azospermia (%) 96 0*
Serum testosterone
(ng/dL)
40±60 705±210*
Serum LH (IU/L) 0.5±1.0 3.0±1.8*
Serum FSH (IU/L) 1.0±1.2 3.2±1.9*

Effects of gonadotropin therapy
During 17 years of follow up, 41 patients, who wished to have children, were treated with hMG and hCG according to the prescribed protocol; of these, 9 failed to comply, while 32 patients completed gonadotropin therapy for at least 12 months (Fig. 1). Testicular size increased in all but 2 men. By six months, mean testicular volume increased from 3.3±1.8 mL to 7.6±1.9 mL (p<0.001) and to 10.9±8.1 mL after 12 months. Serum testosterone concentration increased significantly from 42±34 ng/dL to 281±75 ng/dL in the first month and to 507±220 ng/dL in the fourth month (p<0.001). Spermatozoa were detected in the ejaculate of 2, 9, 16, 20, 23, 25, 26 and 27 patients after 3, 6, 9, 12, 15, 18, 24 and 36 months of therapy respectively.Of 32 patients, who continued hMG/hCG therapy for >1 year, spermatogenesis occurredin 27 (84%), of whom 24(75%) were able to  initiate conception. Mean for number ofspermatozoa at conception was 25.9±17.1 million, and 6 patients had sperm counts below 20 million/mL. Of 24 pregnancies, 5 had abortions, 18 singletons and one twin were born uneventfully. Therefore, >1 yr treatment of 32 men resulted in child birth in 19 pregnancies (59%). Five patients with azospermia had testicular biopsy, of which one had normal spermatogenesis and microinjection resulted in a twin pregnancy; 2 of 3 patients (with sperm counts of 1.2, 4.9 and 10 million), whocould not conceive naturally, underwent assistant fertility procedures and 2 conceived (Fig. 1).There were no correlations between the initial testicular volume and maximum testicular volume after treatment, between initial testicular volume and treatment duration, between maximum sperm counts and initial testicular volume, between ages of the patients at the beginning or after hCG/hMG treatment or between their age and the time of sperm appearing in the ejaculate.

 

fig1

Fig 1. Follow up of 102 patients with hypogonadotropic hypogonadism and the effect of gonadotropin
administration

Discussion
The present study, conducted in a large number of men with HH, shows the effectiveness of testosterone therapy for development of sexual characteristics and the benefits of gonadotropin administration in induction of spermatogenesis and conception. The hormonal deficiency in most patients with hypogonadotropic hypogonadism can betreated with administration of exogenous gonadotropins or GnRH.2,3,10 Gonadotropins are required for fully normal spermatogenesis. FSH is absolutely necessary to initiate spermatogenesis. FSH may stimulate early events in spermatogenesis including spermatogonial proliferation and meiosis.11 In addition, the administration of FSH had a positiverole in sperm  cytostructural parameters.FSH in connection with LH/testosterone is alsofundamental for the maintenance of quantitatively normal spermatogenesis.12 Several treatment regimes are available for patients who have HH and who desire fertility.Humanchorionicgonadotropin (hCG)can be administered in combination with human menopausal gonadotropin (hMG); hCG monotherpy is given until normal serum testosterone levels are achieved. Months of hCG administration may be required before the addition of hMG. Spermatogenesis is observed in 80-90% of patients on this regimen.13 Vicari, in 1992, demonstrated that spermatogenesis can even be induced with hCG per se in HH patients, but the addition of hMG improved the sperm output in some patients.14 Alternative regiments include the use of intermittent injections or pulsatile infusion of GnRH(in men who have intact pituitary function) and highly purified FSH or recombinant FSH (rFSH). Those who do not respond to one regimen may benefit from another;1,6,15- 20 although it takes 6 to 9 months on average before sperm appear in the ejaculate, therapy may be needed for 1 to 3 years, and some patients may not respond at all.1 In the present study, patients were treated by testosterone enanthate until normalization of pubic hair growth and appearance of secondary sexual characteristics. Thirty-two patients also received hCG in combination with hMG treatment for more than one year and spermatogenesis occurred in 84% of patients. Comparison of GnRH therapy with gonadotropin therapy has not shown a difference significant enough to justify the increased expense and inconvenience of GnRH as first-line therapy. GnRH infusion pump therapy is reserved for patients who fail to respond adequately to gonadotropin therapy.21,22 Mean testicular volume significantly increased after hMG/hCG treatment in all of our patients except for 2, and there was no significant correlation between duration of the treatment and maximum testicular volume. There was no remarkable correlation between maximum sperm counts and initial testicular volume or the age of patients at the beginning of treatment, although, it has been reported that initial testicular volume values may predict sperm output in response to hCG/hMG therapy.19 Larger baseline testicular volume, prior gonadotropin therapy, postpubertal status, or the absence of bilateral mal descended testes may positively correlate to the patient’sresponse and hasten the time of sperm detection in the ejaculate.1, 23, 24Although spermatogenesis was induced in 84% of patients and treatment resulted in 75% pregnancies, sperm counts did not reach normal levels in all patients and 6 pregnancies occurred with sperm concentrations below 20 million/mL. Oligospermia with counts below 10 million sperm/mL is common in these patients; however, sperm motility and morphology are usually good. Many patients treated for hypogonadotropic hypogonadism can initiate a pregnancy despite low sperm densities.25 This study has a few limitations. It is a retrospective study and a few patients were lost to follow up. The ability of patients’ wives for ovulation and conception was not studied. The strength of study is that it is one of the largest studies in a general endocrine practice setting. We conclude that testosterone therapy in HH can normalize growth of pubic hair, genitalia growth and secondary sexual characteristics and treatment with gonadotropins are necessary for spermatogenesis and pregnancy induction and should be used for infertile patients with HH.

References: (25)

  1. Schiff JD, Ramírez ML, Bar-Chama N. Medical and surgical management male infertility. Endocrinol Metab Clin North Am 2007; 36: 313-31.
  2. Efesoy O, Cayan S, Akbay E. The efficacy of recombinant human follicle-stimulating hormone in the treatment of various types of male-factor infertility at a single university hospital. J Androl 2009; 30: 679-84.
  3. Siddiq FM, Sigman M. A new look at the medical management of infertility. Urol Clin North Am 2002; 29: 949-63.
  4. Gilbaugh JH 3rd, Lipshultz LI. Nonsurgical treatment of male infertility. An update. Urol Clin North Am 1994; 21: 531-48.
  5. Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol 2002; 147: 617-24.
  6. Kim HH, Schlegel PN. Endocrine manipulation in male infertility. Urol Clin North Am 2008; 35: 303-18
  7. Liu PY, Turner L, Rushford D, McDonald J,Baker HW, Conway AJ, et al. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin- deficient men. Hum Reprod 1999; 14: 1540-5.
  8. Young J, Couzinet B, Chanson P, Brailly S, Loumaye E, Schaison G. Effects of human recombinant luteinizing hormone and follicle- stimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions. J Clin Endocrinol Metab 2000; 85: 3239-44.
  9. Mulligan T, Iranmanesh A, Veldhuis JD. Pulsatile iv infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. J Clin Endocrinol Metab 2001; 86: 5547-53.
  10. Kliesch S, Behre HM, Nieschlag E. Recombinant human follicle-stimulating hormone and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male. Fertil Steril 1995; 63: 1326-8.
  11. Sofikitis N, Giotitsas N, Tsounapi P, Baltogiannis D, Giannakis D, Pardalidis N. Hormonal regulation of spermatogenesis and spermiogenesis. J Steroid Biochem Mol Biol 2008; 109: 323-30.
  12. Nieschlag E, Simoni M, Gromoll J, Weinbauer GF. Role of FSH in the regulation of spermatogenesis: clinical aspects. Clin Endocrinol (Oxf) 1999; 51: 139-46.
  13. Haidl G. Management strategies for male factor infertility. Drugs 2002; 62: 1741-53.
  14. Vicari E, Mongioì A, Calogero AE, Moncada ML, Sidoti G, Polosa P, et al. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism-long-term follow-up. Int J Androl 1992; 15: 20-9.
  15. Bouloux P, Warne DW, Loumaye E; FSH Study Group in Men's Infertility. Efficacy and safety of recombinant human folliclestimulating hormone in men with isolated hypogonadotropic hypogonadism. Fertil Steril 2002; 77: 270-3.
  16. Bouloux PM, Nieschlag E, Burger HG, Skakkebaek NE, Wu FC, Handelsman DJ, et al. Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone. J Androl 2003; 24: 604-11.
  17. Bakircioglu ME, Erden HF, Ciray HN, Bayazit N, Bahçeci M. Gonadotrophin therapy in combination with ICSI in men with hypogonadotrophic hypogonadism. Reprod Biomed Online 2007; 15: 156-60.
  18. Aydos K, Unlü C, Demirel LC, Evirgen O, Tolunay O. The effect of pure FSH administration in non-obstructive azoospermic men on testicular sperm retrieval. Eur J Obstet Gynecol Reprod Biol 2003; 108: 54-8.
  19. Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol 2005; 173: 2072-5.
  20. Delemarre-van de Waal HA. Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism--diagnostic and therapeutic aspects. Eur J Endocrinol 2004; 151 Suppl 3: U89-94.
  21. Liu L, Banks SM, Barnes KM, Sherins RJ. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inceptionof therapy in men with isolated hypogonadotropic hypogonadism. J Clin EndocrinolMetab 1988; 67: 1140-5.
  22. Hetzel WD, Sir-Petermann T, Siebling U, Pfeiffer EF. Normalisation of gonadotropin release by pump assisted pulsatile gonadotropin releasing hormone (GnRH) replacement in hypogonadotropic men. Life Support Syst 1985; 3: 556-60.
  23. Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/ human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases.Eur J Endocrinol 1998; 139: 298-303.
  24. Samli MM, Demirbas M, Guler C. Induction of spermatogenesis in idiopathic hypogonadotropic hypogonadism with gonadotropins in older men. Arch Androl 2004; 50: 267-71.
  25. Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab 2005; 90: 2595-602.